[Alpha heavy chain disease in the presence of a monomeric IgM without excretion of abnormal immunoglobulins].
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006362:Heavy Chain Disease / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007122:Immunoelectrophoresis; D007075:Immunoglobulin M / Q000032:analysis*; D007137:Immunoglobulin alpha-Chains / Q000032:analysis / Q000276:immunology; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D007075:Immunoglobulin M; D007137:Immunoglobulin alpha-Chains; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
Maladie des chaines lourdes alpha avec présence d'une IgM monomérique sans excrétion d'une immunoglobuline anormale.